UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BMC cancer, 2023-07, Vol.23 (1), p.708-708

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Clinical & translational oncology, 2011-03, Vol.13 (3), p.179-184

2011

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-06, Vol.401 (10391), p.1853-1865

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status

Lung cancer (Amsterdam, Netherlands), 2007-05, Vol.56 (2), p.255-262

2007

Link zum Volltext

Verfügbarkeit prüfen

Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency

Chemotherapy (Basel), 2014-01, Vol.60 (5-6), p.353-355

2014

Link zum Volltext

Verfügbarkeit prüfen

Secondary signet-ring cell tumour of the prostate derived from a primary gastric malignancy

Clinical & translational oncology, 2005-10, Vol.7 (9), p.409-411

2005

Link zum Volltext

Verfügbarkeit prüfen

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

The lancet. Gastroenterology & hepatology, 2019-06, Vol.4 (6), p.454-465

2019

Link zum Volltext

Verfügbarkeit prüfen

Progression-free survival as a surrogate endpoint of overall survival in advanced biliary tract cancer: A meta-analysis of randomized trials and individual-patient level correlation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4101-4101

2023

Link zum Volltext

Verfügbarkeit prüfen

MSI exploration in patients with biliary tract cancer from the Spanish RETUD Registry

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.602-602

2023

Link zum Volltext

Verfügbarkeit prüfen

Epidemiological biliary tract cancer characterization: A patient cohort from the Spanish RETUD registry

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.480-480

2022

Link zum Volltext

Verfügbarkeit prüfen

Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer

NEJM evidence, 2024-02, Vol.3 (2), p.EVIDoa2300144

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.15-15

2020

Link zum Volltext

Verfügbarkeit prüfen

The HLA-B7 allele confers susceptibility to breast cancer in Spanish women

Immunology Letters, 2005-11, Vol.101 (2), p.223-225

2005

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3549-3549

2019

Link zum Volltext

Verfügbarkeit prüfen

Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study

Clinical lung cancer, 2005-09, Vol.7 (2), p.121-126

2005

Link zum Volltext

Verfügbarkeit prüfen

Bronchiolitis obliterans organizing pneumonia simulating progression in bronquioloalveolar carcinoma

Clinical & translational oncology, 2006-02, Vol.8 (2), p.133-135

2006

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy

Clinical & translational oncology, 2006-10, Vol.8 (10), p.742-749

2006

Link zum Volltext

Verfügbarkeit prüfen

Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer

Clinical & translational oncology, 2006-12, Vol.8 (12), p.903-911

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Female
(12)
Male
(12)
Middle Aged
(12)
Oncology
(11)
Aged
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Adult
(8)
Gemcitabine
(6)
Life Sciences
(6)
Patients
(6)
Deoxycytidine - Administration & Dosage
(5)
Deoxycytidine - Analogs & Derivatives
(5)
Metastasis
(5)
Biomarkers
(4)
Cancer
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Chemotherapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status

Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency

Secondary signet-ring cell tumour of the prostate derived from a primary gastric malignancy

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group

Progression-free survival as a surrogate endpoint of overall survival in advanced biliary tract cancer: A meta-analysis of randomized trials and individual-patient level correlation

MSI exploration in patients with biliary tract cancer from the Spanish RETUD Registry

Epidemiological biliary tract cancer characterization: A patient cohort from the Spanish RETUD registry

Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer

Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts)

The HLA-B7 allele confers susceptibility to breast cancer in Spanish women

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs)

Continuous-infusion vinorelbine for the treatment of advanced non-small-cell lung cancer: a phase I/II study

Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup

Bronchiolitis obliterans organizing pneumonia simulating progression in bronquioloalveolar carcinoma

Gemcitabine(G)-Erlotinib(E) Versus Gemcitabine-Erlotinib-Capecitabine(C) in the First Line Treatment of Patients with Metastatic Pancreatic Cancer (MPC): Efficacy and Safety Results of a Phase IIB Randomized Study from Spanish TTD Collaborative Group

Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy

Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer

Suchergebnisse filtern